Table 2:

Study schedule.

Assessment	Screening	PIPAC 1				F/U for AE		PIPAC 2				F/U for AE
Week		1				3	6	7				9	12
Day no.	−28 to 0	1	2	3	4	15	36	43	44	45	46	57	78
Informed consent	□
Medical history and demographic	□
Clinico-surgical findings		□						□
Physical examination	□	□	□	□	□	□	□	□	□	□	□	□	□
Vital signs (height at screening only)	□	□	□	□	□	□	□	□	□	□	□	□	□
Performance status	□						□
12-lead ECG	□
FBC	□	□	□	□	□	□	□	□	□	□	□	□	□
Biochemistry	□	□	□	□	□	□	□	□	□	□	□	□	□
Pharmacokinetic assessment		□	□					□	□
Ascites/peritoneal washing	□	□						□
Serum or urine pregnancy test	□
Clinical toxicity assessments		□	□	□	□	□	□	□	□	□	□	□	□
EORTC QLQ-C30	□						□						□
CT imaging	□						□						□